Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan

SYDNEY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX:RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received firm commitments from international and Australian institutional and industry investors (Placement Subscribers), including Lantheus Holdings, Inc. (Lantheus), to raise approximately A$35.0 million (before costs) by way of a private placement (Placement) of 1,167 million new fully paid ordinary shares (approx.) (Placement Shares) in the Company at a price of A$0.03 per share (Placement Price).

Read more at globenewswire.com